| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 34,551 | 6,163 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -20,738 | -32,127 |
| Cash and cash equivalents at beginning of period | 72,054 | - |
| Cash and cash equivalents at end of period | 51,316 | - |
Jasper Therapeutics, Inc. (JSPR)
Jasper Therapeutics, Inc. (JSPR)